Skip to main content

Bank Downgrades Bruker Stock, Cites 'Increasing Competition' in Mass Spec Market

NEW YORK (GenomeWeb News) – UBS today said it has downgraded Bruker BioSciences’ stock to “Neutral" from "Buy."
 
According to Reuters, the brokerage said Bruker’s Daltonics division “faces increasing competition from much larger mass spectrometry vendors, potentially limiting upside.”
 
UBS maintained its $7 price target on Bruker’s stock, Reuters said.
 
The stock was down 1.62 percent, or $.10, at 6.04 in mid-afternoon trading today.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.